Foundayo tablets: a UK guide to orforglipron and assessment

At a glance

Foundayo contains orforglipron, a once-daily prescription GLP-1 medicine. UK authorisation does not mean it is suitable for everyone. Assessment must consider your health, other medicines and follow-up needs. This guide explains the practical questions to discuss before treatment, rather than recommending a medicine for you.

What is Foundayo?

The MHRA authorised orforglipron in August 2026 for weight management and type 2 diabetes. For weight management, its licence covers adults with a BMI of at least 30, or at least 27 with a weight-related health condition, alongside dietary changes and increased physical activity. Meeting a BMI threshold does not by itself establish suitability.

How does it differ from injections and other tablets?

Foundayo is swallowed once daily and contains orforglipron, rather than semaglutide or tirzepatide. It can be taken with or without food; the MHRA describes no food or water restrictions. Wegovy tablets have a different administration routine. Instructions for one medicine must not be applied to another.

A useful way to prepare for assessment is to consider three questions: can you sustain the daily routine, what medicines or health conditions need review, and how will progress and side effects be monitored? Preferring tablets is relevant, but it is only one part of a prescribing decision.

What needs checking before treatment?

Provide a complete list of prescribed medicines, pharmacy medicines and supplements. Mention pregnancy plans, breastfeeding, digestive symptoms and previous reactions to weight-management medicines. Do not start, combine or switch treatments yourself.

The UK prescribing information states that oral hormonal contraception may be less effective. It advises switching to a non-oral method or adding a barrier method for 30 days after starting and for 30 days after each dose increase. Discuss the appropriate plan with your clinician. Foundayo should not be used during pregnancy or breastfeeding; pregnancy planning needs advance advice.

What about side effects and dose changes?

Nausea, vomiting, constipation, diarrhoea, indigestion and abdominal pain can occur. Persistent symptoms need clinical advice, particularly if you cannot maintain fluid intake. Do not assume severe symptoms are simply part of losing weight.

Doses are increased gradually under a prescriber’s direction. Do not increase early because you feel less appetite suppression, or copy a dose mentioned in a study: research may describe a different formulation. Use the prescription label and current patient leaflet.

Questions to bring to your appointment

• What makes this option suitable or unsuitable for my medical history?
• Do my other medicines or contraception need review?
• Who should I contact if symptoms persist?
• When will we review tolerability, nutrition and progress?
• What would make us change or stop the plan?

Frequently asked questions

Can I buy it without a prescription?

No. It is a prescription-only medicine requiring an appropriate clinical assessment.

Is it the same as Wegovy tablets?

No. The active ingredients and administration instructions differ.

Does a tablet remove the need for ongoing support?

No. Treatment still needs review alongside a sustainable eating and activity plan.

Key takeaways

Check the exact medicine and formulation. Share your full medical and medication history. Agree a review and side-effect plan before starting. For information about assessment and ongoing care, read about Puri Pharmacy’s weight-management service.

Urgent symptoms: Get immediate medical advice for severe, lasting stomach pain, particularly if it reaches your back. Call 999 for breathing difficulty or swelling of the face or throat.